Drivers and barriers to acceptance of human-papillomavirus vaccination among young women: a qualitative and quantitative study
- PMID: 20152055
- PMCID: PMC2829006
- DOI: 10.1186/1471-2458-10-68
Drivers and barriers to acceptance of human-papillomavirus vaccination among young women: a qualitative and quantitative study
Abstract
Background: Human papillomavirus (HPV) is a necessary cause of cervical dysplasia and cancer, and of genital warts. Few studies have examined attitudes to HPV vaccination since the introduction of HPV vaccines. We aimed to investigate the reasons for young women's acceptance or rejection of the quadrivalent HPV vaccine after its general availability in Denmark.
Method: A literature review assessed attitudes towards HPV vaccination and the information was used to identify relevant questions for telephone and focus group interviews with women aged 16-26 who had decided to receive or reject HPV vaccination. 435 women across Denmark were interviewed by telephone. Qualitative interviews were undertaken in focus groups with 33 women living in Odense who had completed the telephone survey. Four focus groups were set up according to age (16-20 and 21-26 years of age) and acceptance/rejection of the vaccine.
Results: Of 839 women initially contacted by telephone, 794 were included, 411 (49%) said they accepted vaccination but only 201 (24%) had actually received the vaccine and these latter were interviewed. 242 women said they refused vaccination of which 234 were interviewed. Women who were undecided were excluded from the study. Prevention of cervical cancer was the main driver for acceptance of the vaccine, followed by parental encouragement and financial support, personal experience of someone with cancer and recommendation by health-care professionals. The greatest barrier to vaccination was its cost. A lack of information about the benefits of vaccination for sexually active women was also an important barrier and the older participants in particular considered that they were too old to be vaccinated. Knowledge about HPV and its role in the development of cervical cancer and genital warts was poor.
Conclusions: The difference between intention to be vaccinated and starting vaccination was considerable, and a large proportion of women aged 16-26 did not wish to be vaccinated. If the most important barriers to vaccination were addressed (cost and a lack of information about vaccination benefits), it is likely that the uptake of vaccination in Denmark would increase substantially.
Figures
Similar articles
-
Facilitators and barriers of human papillomavirus vaccine uptake in young females 18-26 years old in Singapore: A qualitative study.Vaccine. 2019 Sep 24;37(41):6030-6038. doi: 10.1016/j.vaccine.2019.08.053. Epub 2019 Aug 28. Vaccine. 2019. PMID: 31473002
-
French women's knowledge of and attitudes towards cervical cancer prevention and the acceptability of HPV vaccination among those with 14 - 18 year old daughters: a quantitative-qualitative study.BMC Public Health. 2012 Nov 27;12:1034. doi: 10.1186/1471-2458-12-1034. BMC Public Health. 2012. PMID: 23186288 Free PMC article.
-
HPV vaccine promotion: does referring to both cervical cancer and genital warts affect intended and actual vaccination behavior?Womens Health Issues. 2011 Jan-Feb;21(1):71-9. doi: 10.1016/j.whi.2010.08.004. Womens Health Issues. 2011. PMID: 21185992
-
Barriers to human papillomavirus vaccine acceptability in Israel.Vaccine. 2013 Nov 22;31 Suppl 8:I53-7. doi: 10.1016/j.vaccine.2013.06.107. Vaccine. 2013. PMID: 24229720 Review.
-
HPV vaccine acceptance among women in the Asian Pacific: a systematic review of the literature.Asian Pac J Cancer Prev. 2010;11(3):641-9. Asian Pac J Cancer Prev. 2010. PMID: 21039030
Cited by
-
Predictors, barriers and motivating factors for human papillomavirus vaccination and testing as preventive measures for cervical cancer: A study of urban women in Lagos, Nigeria.Prev Med Rep. 2021 Nov 15;24:101643. doi: 10.1016/j.pmedr.2021.101643. eCollection 2021 Dec. Prev Med Rep. 2021. PMID: 34987955 Free PMC article.
-
"Knowledge and attitudes of Spanish adolescent girls towards human papillomavirus infection: where to intervene to improve vaccination coverage".BMC Public Health. 2014 May 22;14:490. doi: 10.1186/1471-2458-14-490. BMC Public Health. 2014. PMID: 24885391 Free PMC article.
-
The Impact of Socio-Economic Determinants on the Vaccination Rates with Rotavirus and Human Papiloma Virus Vaccine.Zdr Varst. 2015 Dec 16;55(1):43-52. doi: 10.1515/sjph-2016-0007. eCollection 2016 Mar. Zdr Varst. 2015. PMID: 27647088 Free PMC article.
-
Factors that influence caregivers' and adolescents' views and practices regarding human papillomavirus (HPV) vaccination for adolescents: a qualitative evidence synthesis.Cochrane Database Syst Rev. 2025 Apr 15;4(4):CD013430. doi: 10.1002/14651858.CD013430.pub2. Cochrane Database Syst Rev. 2025. PMID: 40232221 Free PMC article.
-
The Prevalence of High Carcinogenic Risk of HPV Genotypes among HIV-Positive and HIV-Negative MSM from Russia.Can J Infect Dis Med Microbiol. 2021 May 31;2021:6641888. doi: 10.1155/2021/6641888. eCollection 2021. Can J Infect Dis Med Microbiol. 2021. PMID: 34122681 Free PMC article.
References
-
- Ferlay J, Bray F, Pisani P, Parkin DM. IARC CancerBase No. 5, version 2.0. Lyon: IARCPress; 2004. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide.
-
- Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247–1255. doi: 10.1016/S0140-6736(06)68439-0. - DOI - PubMed
-
- Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009;373:1949–1957. doi: 10.1016/S0140-6736(09)60691-7. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical